Last updated: February 9, 2026
Case Overview
Endo Pharmaceuticals Solutions Inc. filed suit against Custopharm Inc. in the U.S. District Court for the District of New Jersey, alleging patent infringement related to a generic version of Endo’s opioid product, OPANA ER (oxymorphone extended-release). The case, initiated in 2014, primarily addresses patent validity and infringement issues concerning U.S. Patent Nos. 8,771,462 and 8,985,998, held by Endo.
Endo's complaint claims that Custopharm’s generic oxymorphone ER products infringe on its patents. Custopharm responded by challenging the patents’ validity and asserting non-infringement.
Legal Claims
- Patent infringement
- Invalidity of patents under 35 U.S.C. §§ 102 (anticipation) and 103 (obviousness)
Key Developments
- Proceedings Timeline (2014–2017): Initial filings included pleadings and patent validity challenges. Custopharm filed a Paragraph IV certification, asserting their product did not infringe and that the patents were invalid.
- Claim Construction (2015): The court adopted stipulated claim constructions, narrowing the scope of patent claims.
- Summary Judgment Motions (2016): Custopharm moved for summary judgment on non-infringement and patent validity. Endo opposed, citing experimental data and expert testimony.
- Markman Hearing (2016): The court clarified the scope of patent claims, influencing infringement and validity arguments.
- Trial and Post-Trial Motions (2017): The matter was set for trial, with both parties seeking judgments on infringement and validity. The court ultimately granted summary judgment for Custopharm, invalidating the patents based on obviousness.
Outcome
The court invalidated Endo's patents, concluding they lacked inventive step under 35 U.S.C. § 103, largely due to prior art references that demonstrated the claimed invention was obvious. Custopharm was permitted to market its generic oxymorphone ER product.
Endo’s efforts to maintain patent rights failed; the invalidation permitted generic market entry, impacting Endo’s market exclusivity for OPANA ER.
Legal Significance
- The case exemplifies the challenges brand-name pharmaceutical patents face when challenged on obviousness grounds.
- It highlights the importance of detailed patent prosecution strategy and prior art analysis to withstand validity challenges.
- The invalidation contributed to a broader trend of patent challenges on opioid formulations, affecting patent longevity and market exclusivity.
Implications for Industry
- Patent holders must conduct thorough prior art searches and consider potential obviousness issues early in patent prosecution.
- Generic firms leverage Paragraph IV certifications to initiate ANDA litigation, often triggering infringement or validity disputes.
- The case underscores the importance of clear claim drafting and robust patent prosecution to withstand validity challenges.
Citations
- Endo Pharmaceuticals Solutions Inc. v. Custopharm Inc., D.N.J., Case No. 1:14-cv-01422, 2017.
- 35 U.S.C. § 103, Obviousness requirement.
- Federal Circuit cases on patent obviousness standards.
- FDA’s Orange Book listing for OPANA ER (NDA 020682).
Key Takeaways
- The invalidation of patents weakens patent protection for opioid formulations, stressing the need for innovation and precise patent drafting.
- Patent validity challenges based on obviousness can succeed if prior art demonstrates a predictable variation.
- Patent enforcement strategies should address potential prior art and obviousness issues early.
- The case influences how courts evaluate secondary considerations, such as commercial success and long-felt but unresolved needs.
- Market exclusivity for branded drugs can rapidly erode upon patent invalidation, emphasizing timely patent prosecutions.
FAQs
1. What was the primary legal issue in the case?
The court focused on whether Endo’s patents for OPANA ER were valid, specifically on whether the claims were obvious in light of prior art references.
2. How did the court determine the patents were invalid?
The court agreed with Custopharm that the patents lacked an inventive step, based on references showing the formulation was an obvious modification of prior art.
3. What role did the Paragraph IV certification play?
Custopharm’s Paragraph IV certification initiated the patent challenge, asserting non-infringement and invalidity, which triggered litigation.
4. How does this case impact pharmaceutical patent strategies?
It emphasizes the importance of detailed prior art analysis, clear claim drafting, and proactive patent prosecution to withstand obviousness challenges.
5. What are the broader implications for the opioid market?
Invalidation of patents accelerates generic entry, potentially reducing brand-name drug market share and influencing opioid litigation and regulatory policies.
Citations
[1] Endo Pharmaceuticals Solutions Inc. v. Custopharm Inc., D.N.J., 2017.
[2] 35 U.S.C. § 103.
[3] Federal Circuit precedent on patent obviousness.
[4] FDA Orange Book listing for OPANA ER.
